Results 161 to 170 of about 6,317 (201)

Benralizumab

Reactions Weekly
  +11 more sources

Benralizumab

Reactions Weekly, 2022
  +7 more sources

Benralizumab

Reactions Weekly, 2023
openaire   +2 more sources

Benralizumab: First Global Approval

Drugs, 2018
Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD).
openaire   +2 more sources

Benralizumab

Reactions Weekly, 2021
openaire   +2 more sources

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

Lancet Respiratory Medicine,the, 2022
Andrew Menzies-Gow, Mark Gurnell, Liam G Heaney   +2 more
exaly  

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

Chest, 2021
Jaideep Dhariwal, Grainne D'ancona, Abdel Douiri   +2 more
exaly  

Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis

Journal of Allergy and Clinical Immunology: in Practice, 2021
Vamsi P Guntur, Laurie Manka, Joshua L Denson   +2 more
exaly  

Benralizumab

Drugs of the Future, 2014
openaire   +1 more source

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2020
Ioana Agache, Cezmi A Akdis, Mubeccel Akdis   +2 more
exaly